C. Espenschied

发表

Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.

C. Gau, H. LaDuca, H. Hampel, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Secondary Germline Finding in Liquid Biopsy of a Deceased Patient; Case Report and Review of the Literature

A. Barzi, V. Raymond, C. Ricker, 2018, Front. Oncol..

Monoallelic MUTYH carrier status is not associated with increased breast cancer risk in a multigene panel cohort

H. LaDuca, K. Jasperson, M. Black, 2019, Familial Cancer.

Unexpected CDH1 Mutations Identified on Multigene Panels Pose Clinical Management Challenges.

Julie O. Culver, S. Gruber, Kevin J. McDonnell, 2017, JCO precision oncology.

Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy

Sharyn I. Katz, C. Langer, S. Yee, 2021, JCO precision oncology.

Closing the Loop: Action Research in a Multimodal Hereditary Cancer Patient Conference is an Effective Tool to Assess and Address Patient Needs

J. Weitzel, K. Blazer, D. Macdonald, 2012, Journal of Cancer Education.

Hereditary leukemia due to rare RUNX1c splice variant (L472X) presents with eczematous phenotype.

J. Weitzel, R. Bhatia, P. Parker, 2012, International journal of clinical medicine.

Monoallelic MUTYH carrier status is not associated with increased breast cancer risk in a multigene panel cohort

H. LaDuca, K. Jasperson, M. Black, 2019, Familial Cancer.

050 Lifetime Persistent Genital Arousal Disorder: Management of PGAD in an Adolescent

I. Goldstein, C. Espenschied, S. King, 2016 .

Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database

Rodney J Scott, John-Paul Plazzer, Finlay Macrae, 2013, Nature Genetics.

ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).

M. Ahn, E. Cho, Dong-Wan Kim, 2020 .

Tumor Protein p53 (TP53) Testing and Li-Fraumeni Syndrome

J. Weitzel, J. Culver, A. Sorrell, 2013, Molecular Diagnosis & Therapy.

Tumor Protein p53 (TP53) Testing and Li-Fraumeni Syndrome

Julie O. Culver, J. Weitzel, J. Culver, 2013, Molecular Diagnosis & Therapy.

Clinical germline diagnostic exome sequencing for hereditary cancer: Findings within novel candidate genes are prevalent.

K. Nathanson, H. LaDuca, E. Chao, 2018, Cancer genetics.

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases

S. Mortimer, J. Riess, D. Gandara, 2020, Cancer.

Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center

M. Cobleigh, T. Kuzel, H. LaDuca, 2020, Cancer reports.

Spectrum of mismatch repair gene mutations and clinical presentation of Hispanic individuals with Lynch syndrome.

S. Gruber, J. Weitzel, Annette Y. Sunga, 2017, Cancer genetics.

Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.

R. Doebele, C. Baik, K. Reckamp, 2020, Clinical lung cancer.

Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results.

J. Weitzel, K. Blazer, D. Macdonald, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TumorNext-Lynch-MMR: a comprehensive next generation sequencing assay for the detection of germline and somatic mutations in genes associated with mismatch repair deficiency and Lynch syndrome

Sitao Wu, M. Janicek, H. Rana, 2018, Oncotarget.

Closing the Loop: Action Research in a Multimodal Hereditary Cancer Patient Conference is an Effective Tool to Assess and Address Patient Needs

J. Weitzel, K. Blazer, D. Macdonald, 2012, Journal of Cancer Education.

Advances in the diagnosis of hereditary kidney cancer: Initial results of a multigene panel test

B. Shuch, H. LaDuca, K. Brierley, 2017, Cancer.

A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors.

J. Ahn, M. Ahn, E. Cho, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database Study.

T. Bekaii-Saab, J. Strickler, L. Hsu, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non–Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic

J. Chmielecki, J. Gray, A. Telaranta-Keerie, 2023, The Journal of Molecular Diagnostics.

ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition

A. Wang-Gillam, M. Nezami, K. Mody, 2024, Frontiers in oncology.